The mission of ADVANCE-ID is to conduct high-quality clinical trials that have a global impact on management of infections. With the support of a multi-million dollar grant from the Wellcome Trust, ADVANCE-ID seeks expressions of interest from companies developing novel antimicrobial agents. The purpose of the grant is to conduct a Phase II clinical trial in the ADVANCE-ID network. In limited circumstances (for example, when a company is planning to skip from Phase I trials directly to a Phase III trial), a Phase III clinical trial may be considered. Data from the trial will be of sufficient quality to be included in the package for a New Drug Application to be submitted to the FDA, EMA and other similar organisations.

The Phase II trial will be conducted in close collaboration between ADVANCE-ID and the company developing the novel antimicrobial agent. It is anticipated that the award will cover the cost of a Phase II trial but depending on the complexity of the trial and other variables, the company developing the novel antimicrobial agent may need to co-contribute financially. If a Phase III trial is being considered, additional funding will definitely be required, and it may be appropriate to involve other geographic locations and/or clinical research networks and funders in the trial.